PODD logo

PODD

Insulet Corporation

$295.54
+$0.35(+0.12%)
51
Overall
40
Value
36
Tech
78
Quality
Market Cap
$20.84B
Volume
287.08K
52W Range
$230.05 - $354.88
Target Price
$381.00

Company Overview

Mkt Cap$20.84BPrice$295.54
Volume287.08KChange+0.12%
P/E Ratio49.8Open$296.45
Revenue$2.1BPrev Close$295.19
Net Income$418.3M52W Range$230.05 - $354.88
Div YieldN/ATarget$381.00
Overall51Value40
Quality78Technical36

No chart data available

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Sector: Healthcare
Industry: Medical Devices

Latest News

3 “Strong Buy” Growth Stocks to Buy Now, According to Analysts – 12/8/2025

Growth stocks reflect firms on track for swift expansion, beating peers and the overall market. Their strategy to reinvest profits drives continued...

Radhika Saraogi3 days ago

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (BIOA) and Insulet (PODD)

Christine Brown8 days ago

Morgan Stanley Keeps Their Buy Rating on Insulet (PODD)

TipRanks Auto-Generated Intelligence Newsdesk8 days ago

Insulet (PODD) Gets a Buy from Truist Financial

TipRanks Auto-Generated Intelligence Newsdesk21 days ago

RBC Capital Remains a Buy on Insulet (PODD)

TipRanks Auto-Generated Intelligence Newsdesk21 days ago
ABCD
1SymbolPriceChangeVol
2PODD$295.54+0.1%287.08K
3
4
5
6

Get Insulet Corporation Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.